Natalia Kinijevich

Natalia Kinijevich, a Bloomberg News equities reporter specializing in market-moving companies, dives into recent stock developments. She discusses Novo Nordisk's major win with the U.S. approval of its oral Wegovy pill, setting up a competitive race against Eli Lilly. Natalia also analyzes ServiceNow's $7.75 billion acquisition of cybersecurity firm Armis, highlighting its significance for enterprise security. Finally, she covers the sharp 30% rise in Sable's shares following regulatory approval for a pipeline restart amid its challenging past.